BioMed Research International / 2014 / Article / Tab 1

Clinical Study

Transarterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Prognostic Factors in a Single-Center Study of 188 Patients

Table 1

Patient baseline characteristics ( ).

ParameterNumber %

Age/years, mean (range)  49.89 (18–80)
Gender
 Male16788.3
 Female2111.2
Ascites
 Yes5127.1
 No13772.9
Tumor size/cm, mean (range)   8.8 (2–18.8)
Number of tumor lesions
 ≥310254
 <38646
Extrahepatic metastasis
 Yes2211.7
 No16688.3
Type of PVTT
 Type I9047.9
 Type II9852.1
Arteriovenous Fistula
 Yes3217
 No15683
Child-Pugh class
 A15280.9
 B3619.1
ECOG
 0189.6
 116889.4
 221.1
Laboratory tests, mean (range)
 Alpha fetoprotein 40486 (1–121000)
 Hemoglobin (g/L)130.1 (80–193)
 Platelets (109/L)146.8 (25–480)
 International normalized ratio 1.5 (0.83–38.3)
 Alanine aminotransferase (U/L)53.7 (5–984)
 Aspartate aminotransferase (U/L)83.8 (15–1242)
 Albumin (g/L)37.8 (24–50.4)
 Total bilirubin ( mol/L)20.1 (6–112)
 Creatinine80.2 (43–193)

BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; AFP: -fetoprotein; PVTT: portal vein tumor thrombosis.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.